JP2012525369A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012525369A5 JP2012525369A5 JP2012507839A JP2012507839A JP2012525369A5 JP 2012525369 A5 JP2012525369 A5 JP 2012525369A5 JP 2012507839 A JP2012507839 A JP 2012507839A JP 2012507839 A JP2012507839 A JP 2012507839A JP 2012525369 A5 JP2012525369 A5 JP 2012525369A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- use according
- group
- alkyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 23
- 238000001356 surgical procedure Methods 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 7
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 5
- 229940002612 prodrug Drugs 0.000 claims 5
- 239000000651 prodrug Substances 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- -1 phosphonotetrahydropyran compound Chemical class 0.000 claims 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 3
- 230000029663 wound healing Effects 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000002316 cosmetic surgery Methods 0.000 claims 2
- 150000005690 diesters Chemical class 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 210000002615 epidermis Anatomy 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 1
- 102000016359 Fibronectins Human genes 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021945 Tendon injury Diseases 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 229960004308 acetylcysteine Drugs 0.000 claims 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 claims 1
- XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 claims 1
- 229950001858 batimastat Drugs 0.000 claims 1
- 229960003065 bosentan Drugs 0.000 claims 1
- GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- 210000002744 extracellular matrix Anatomy 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 229960002411 imatinib Drugs 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 208000011379 keloid formation Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 229960004584 methylprednisolone Drugs 0.000 claims 1
- 229960001476 pentoxifylline Drugs 0.000 claims 1
- 229960003073 pirfenidone Drugs 0.000 claims 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 229960004586 rosiglitazone Drugs 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- 210000001835 viscera Anatomy 0.000 claims 1
- 0 *C(OC(*)=O)OP(CC[C@]([C@@]([C@@]1O)O)O[C@](*)[C@]1N=O)(OC(*)OC(*)=O)=O Chemical compound *C(OC(*)=O)OP(CC[C@]([C@@]([C@@]1O)O)O[C@](*)[C@]1N=O)(OC(*)OC(*)=O)=O 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17341609P | 2009-04-28 | 2009-04-28 | |
| US61/173,416 | 2009-04-28 | ||
| PCT/IB2010/000960 WO2010125445A1 (en) | 2009-04-28 | 2010-04-28 | Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012525369A JP2012525369A (ja) | 2012-10-22 |
| JP2012525369A5 true JP2012525369A5 (cg-RX-API-DMAC7.html) | 2013-06-20 |
Family
ID=43031758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012507839A Pending JP2012525369A (ja) | 2009-04-28 | 2010-04-28 | 創傷および線維性障害の治療のためのホスホテトラヒドロピラン化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8557783B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2424542A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2012525369A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20120049183A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010243314C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2760253A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL215990A0 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ596419A (cg-RX-API-DMAC7.html) |
| SG (1) | SG175816A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010125445A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2926480A1 (en) * | 2012-11-15 | 2014-05-22 | Tufts University | Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor |
| JP7466927B2 (ja) * | 2018-08-10 | 2024-04-15 | ニューヨーク ユニバーシティ | アンジェルマン症候群及び自閉症を治療するためのｉｇｆ―２受容体作動剤リガンドの使用 |
| WO2020033972A1 (en) | 2018-08-10 | 2020-02-13 | New York University | Use of mannose 6 phosphate and modifications thereof for memory enhancement and reducing memory impairment |
| CN113301925A (zh) | 2018-12-19 | 2021-08-24 | 小利兰·斯坦福大学理事会 | 用于溶酶体靶向的双官能分子以及相关的组合物和方法 |
| CN113368106B (zh) * | 2020-02-25 | 2023-09-29 | 渐宽(苏州)生物科技有限公司 | 艾托莫德用于防治特发性肺纤维化的药物中的用途 |
| CN113288890B (zh) * | 2021-06-21 | 2022-02-22 | 南方医科大学南方医院 | N-乙酰-l-半胱氨酸在制备预防和/或治疗运动损伤的药物中的应用 |
| CA3226269A1 (en) | 2021-07-14 | 2023-01-19 | Lycia Therapeutics, Inc. | Asgpr cell surface receptor binding compounds and conjugates |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ872300A0 (en) * | 2000-07-11 | 2000-08-03 | Praxis Pharmaceuticals Pty Ltd | Compounds and methods |
| DE602004022659D1 (de) * | 2003-05-20 | 2009-10-01 | Pharmaxis Pty Ltd | Mannose-6-phosphonat-verbindungen zur behandlung von entzündungskrankheiten |
| FR2930942B1 (fr) | 2008-05-07 | 2011-03-04 | Centre Nat Rech Scient | Nouvelles utilisations de derives de d-mannopyranose activateurs de l'angiogenese |
| FR2930943B1 (fr) | 2008-05-07 | 2011-03-18 | Centre Nat Rech Scient | Nouvelles utilisations de derives de d-mannopyranose inhibiteurs de l'angiogenese |
-
2010
- 2010-04-28 JP JP2012507839A patent/JP2012525369A/ja active Pending
- 2010-04-28 WO PCT/IB2010/000960 patent/WO2010125445A1/en not_active Ceased
- 2010-04-28 US US13/318,065 patent/US8557783B2/en not_active Expired - Fee Related
- 2010-04-28 EP EP10769382A patent/EP2424542A4/en not_active Withdrawn
- 2010-04-28 NZ NZ596419A patent/NZ596419A/en not_active IP Right Cessation
- 2010-04-28 AU AU2010243314A patent/AU2010243314C1/en not_active Ceased
- 2010-04-28 KR KR1020117028281A patent/KR20120049183A/ko not_active Withdrawn
- 2010-04-28 CA CA2760253A patent/CA2760253A1/en not_active Abandoned
- 2010-04-28 SG SG2011079274A patent/SG175816A1/en unknown
-
2011
- 2011-10-27 IL IL215990A patent/IL215990A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012525369A5 (cg-RX-API-DMAC7.html) | ||
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| JP5917555B2 (ja) | ケモカイン受容体調節因子としてのリン酸誘導体 | |
| WO2012107706A8 (en) | Phenothiazine diaminium salts and their use | |
| EA201391263A1 (ru) | Комбинированные терапии гематологических опухолей | |
| JP2018519343A5 (cg-RX-API-DMAC7.html) | ||
| JP2017511815A5 (cg-RX-API-DMAC7.html) | ||
| AR059425A1 (es) | Amidas ciclicas condensadas del acido bencensulfonico, un metodo para su preparacion, composiciones farmaceuticas que las contienen y el empleo de las mismas en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de l-cpt1 | |
| JP2013532652A5 (cg-RX-API-DMAC7.html) | ||
| JP2014510774A5 (cg-RX-API-DMAC7.html) | ||
| JP2018511647A5 (cg-RX-API-DMAC7.html) | ||
| CN103249737A (zh) | 作为精氨酸酶抑制剂的硼酸盐 | |
| JP2016529235A5 (cg-RX-API-DMAC7.html) | ||
| ME02554B (me) | Ibat inhibitori za lečenje bolesti jetre | |
| RU2012112050A (ru) | Производные дигидроптеридинона, способ их получения и фармацевтическое применение | |
| RU2016151420A (ru) | Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий | |
| RU2013150332A (ru) | Замещенные бициклические метиламинные производные как модуляторы рецепторов сфингозин-1-фосфата | |
| JP2016531126A5 (cg-RX-API-DMAC7.html) | ||
| JP2012508251A5 (cg-RX-API-DMAC7.html) | ||
| JP2013525286A5 (cg-RX-API-DMAC7.html) | ||
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| JP7089062B2 (ja) | 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Ｂｃｌファミリーアンタゴニストであるホスホリジン | |
| AR073230A1 (es) | Derivados del acido benzofuran-piridin carbamico, utiles en la preparacion de compuestos marcados, proceso para prepararlos y proceso para preparar precursores de sintesis. | |
| JP2008517897A5 (cg-RX-API-DMAC7.html) | ||
| TW201733579A (zh) | 用於傷口癒合及預防疤痕之方法 |